JPS5946222A - Carcinostatic agent - Google Patents

Carcinostatic agent

Info

Publication number
JPS5946222A
JPS5946222A JP57156739A JP15673982A JPS5946222A JP S5946222 A JPS5946222 A JP S5946222A JP 57156739 A JP57156739 A JP 57156739A JP 15673982 A JP15673982 A JP 15673982A JP S5946222 A JPS5946222 A JP S5946222A
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
glucose
compound
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57156739A
Other languages
Japanese (ja)
Other versions
JPH0136809B2 (en
Inventor
Hideaki Matsuda
松田 秀明
Tatsuhiko Katori
香取 達彦
Tetsuo Ikegawa
哲郎 池川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SSP Co Ltd
Original Assignee
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd filed Critical SSP Co Ltd
Priority to JP57156739A priority Critical patent/JPS5946222A/en
Publication of JPS5946222A publication Critical patent/JPS5946222A/en
Publication of JPH0136809B2 publication Critical patent/JPH0136809B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To provide a carcinostatic agent having extremely low toxicity, by using a D-glucose-3-O-alkyl (or alkenyl) ether as an active component. CONSTITUTION:The objective agent contains the compound of formula I (R is 1-30C alkyl or 1-30C alkenyl), e.g. D-glucose-3-O-lauryl ether, as an active component. The compound of formula I can be prepared easily by refluxing the 3-O-alkyl (or alkenyl)-1,2:5,6-di-O-isopropylidene-alpha-D-glucofuranose of formula IIin an aqueous solution in the presence of an acid catalyst such as a mineral acid, acidic ion exchange resin, etc. Dose: preferably 1.0-200mg/kg for oral administration and 0.5-100mg/kg for parenteral administration for adult.

Description

【発明の詳細な説明】 本発明はD−グルコース−6−しJ−アルキル若1−〈
はアルケニルエーテル令・仔効tJy分として含有する
抗癌剤に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention provides D-glucose-6- and J-alkyl-
relates to an anticancer agent containing an alkenyl ether as an active ingredient.

本発明者らは種々のグルコースエーテル填ニつい−(、
その礒埋作用馨検討(2ていたところ、D−グルコース
−6−〇−了ルギル庁しくj工了ルケニルエーテルが特
異的に1jΦい仇41¥i作用ケ有することr見出し、
本狛四を完成した。
The present inventors have developed various glucose ether loadings (
Investigation of its embedding effect (2) revealed that D-glucose-6-〇-alkenyl ether has a specific 1jΦ harmful effect,
Completed Honkomashi.

すなわち、本発明は仄の式(1) (式中、Rは炭素数1〜6Uのアルキルまたはアルケニ
ル基を示す) で表わされるD−グルコース−3−(J−アルキル若し
くはアルケニルエーテル’&N効成分として含有する仇
希削ゲ提+3”するものである。
That is, the present invention provides a D-glucose-3-(J-alkyl or alkenyl ether'&N active ingredient) represented by the following formula (1) (wherein R represents an alkyl or alkenyl group having 1 to 6 U) It increases the amount of damage it contains by +3".

本発明のD−グルコース−6−(l−アルキル若しくは
アルケニルエーテルは、公知の化合物であるか、又は公
知の方法fよって容易に64浩さIt、ろ化合物である
。1該1に合物に向しては、−Cでに、例えばTr、−
Mezhdunar、 Kongr、 Pooerkh
n、−Akt %Veshcl+estuan、7 t
l〕1976 (Pub、 1977 、)、1.21
7−1,223(()er)、及びNats、 Kom
 。
The D-glucose-6-(l-alkyl or alkenyl ether of the present invention) is a known compound or is easily a filtrate compound by known methods. For example, Tr, -
Mezhdunar, Kongr, Pooerkh
n, −Akt%Veshcl+estuan, 7t
l]1976 (Pub, 1977,), 1.21
7-1,223(()er), and Nats, Kom
.

5SSFt  Pouerkhn、    J’J−t
、Vesbchestuarn  :  MO5COw
5SSFt Pouerkhn, J'J-t
, Vesbchestuarn: MO5COw
.

USSRにW面C舌性剤としてのD−グルコース−6−
IJ −、(:’12アルギルエーテルが開示されてお
り、f、fこ戻素数1〜4のD−グルコース−3−U−
アルギルエーテル及びアリルエーテルも知られている。
D-glucose-6- as a W-face C tongue agent in USSR
IJ-, (:'12 argyl ether is disclosed, f, f return prime number 1 to 4 D-glucose-3-U-
Argyl ethers and allyl ethers are also known.

(−かしなから、これらにつ(ハての仇・lv1作用等
(−「♀< q:nられていなかった。
(-Kashina, these things (Hate's enemy, lv1 effect, etc.) (-"♀< q:n were not mentioned.

本発明のD−グルコース−ろ−〇−アルキル若しくはア
ルケニルエーテル(1)の抗層作用は特異的なものであ
り、1シリえげ1位のアルキルエーテルでほその作用は
約1//Lo・1呈IWと弱くなる。
The anti-layer effect of the D-glucose-lo-〇-alkyl or alkenyl ether (1) of the present invention is specific, and the anti-layer effect is approximately 1//Lo- It becomes weaker with 1 IW.

本発明のD−グルコース−3=[J−アルキル若シ<(
エアルケニルエーテル(1)は例1えは次の反応式に従
い製造することができる。
D-glucose-3=[J-alkyl<(
Airkenyl ether (1) can be prepared according to Example 1 and the following reaction formula.

(式中、Rは前6己と同じ) すなわち、5−o−’yルキル若しくはアルケニル−1
,2:!l)、6−ゾーO−インプロピリデンLtχ−
1〕−ゲルコフラノース叩馨は触媒の存&E ’F。
(In the formula, R is the same as above) That is, 5-o-'ylkyl or alkenyl-1
,2:! l), 6-zo-O-inpropylidene Ltχ-
1] - Gelcofuranose activation is the presence of a catalyst.

水浴液中で還流″rることにより芥易に侍られ4)。It can be prepared easily by refluxing it in a water bath 4).

I賛)触媒としては、1兎)賀、堪1嗅浄の拡11a及
び−1ンノメーライトI R−120% CG −12
11等の酸11イオン文I!+!! l!J脂が用いら
れる。反応(工、3’0分ないし5U時1111瀉流ゲ
Jになうことにより完結する。
I praise) As a catalyst, 1 rabbit) Ka, Kan 1 olfactory expansion 11a and -1 Nnomerite I R-120% CG-12
11th grade acid 11 ion sentence I! +! ! l! J fat is used. Reaction (technique) is completed by becoming 1111 flow game J at 3'0 minutes to 5U.

斯くして(44られfこ反L6生成物から化自′吻(1
)の収得は、目的I勿か水にシ11「浴であり」場合レ
エ、そのまま(及引/I3過¥るか、エーテル与の・1
−J′ぜし者媒で抽出することによりAdこなわれ、ま
た、(」曲物が水浴性であり、−役〕咄媒として1払醒
ケ用いた場合は、適当なアルカリ等で中第11シたのち
/lり?減圧留去することに3r、す、目的物が水溶性
で;bす、1種触媒としてイオン交侯11i脂を用いた
場合(・土、−rオン交(め反1脂ン戸崗陵、7p諷ン
C或圧!f滝、1宿することによりそれぞれおこなわl
る。。
In this way, (44) is converted from the L6 product (1
), the objective I of course is to water.11 If it is a bath, then as it is (reference/I3 excess or 1 of ether)
Ad can be carried out by extraction with a suitable medium, and if the curved material is water-bathable and is used as a water bathing medium, it can be extracted with a suitable alkali etc. After the 11th cycle, the target product is water-soluble; (Metan 1 Fatty King Mausoleum, 7p Licensing C Orpressure! F Waterfall, each done by staying 1 night.
Ru. .

叙上の釦ぐして(iられ1こ化訃物(1)の粗結晶は、
−に、メタノール、エタノール、n−ゾロパノール、イ
ソゾロパノール等のアルコールづハ、アセトン、メチル
エチルケトン等のケト〉′iA;hるいは水等又はこれ
らの組合1tによる溶媒から再結晶することにより、1
11j枠なダルコー スー5−IJ−アルギル一台シ<
はアルケニルエーテルの4吉晶とfることかできる。
The crude crystals of the 1-carved mortuary (1) are as follows:
-, alcohols such as methanol, ethanol, n-zolopanol, isozolopanol, ketones such as acetone, methyl ethyl ketone, etc.;
11j frame Darko Sue 5-IJ-Argil one unit
can be considered as the four lucky crystals of alkenyl ether.

斗“216明化合物の出発原料であろ3−0−アルキル
−J L < &Xアルケニルー −イソプロピリデン−α−D−グルコフラノースful
のうぢ、炭素故1、2、6、4、12およびアリルエー
テルについては公知16合物であるか,その他のものは
り[硯rヒ金物である。これらの化合物は、1 、2:
5,6−ジーD−イソプロピリデン−αーDーグルコフ
ラノースゲ31そ当な溶媒に溶解し、1〜2当+1 ’
0、)水素化ナトIIウム等の強塩基の存在下1〜2当
給のアルキル若しくはアルケニルハライげン[)〜ε3
−0°CでUユ5〜10時間反応さすることにより容易
に製造することができる。溶媒としてはベンゼン、トル
エン、ゾオギナン、デトラヒドロフラン、ゾメチルスル
ホギシド、ジメチルホルムアミド等か1史用て・きるが
、時にジメチルスルホキシ1か好.ヂしい。
The starting material for Dou'216 Ming compound is 3-0-alkyl-J L <&X alkenyl-isopropylidene-α-D-glucofuranose ful
Regarding carbon atoms 1, 2, 6, 4, 12, and allyl ethers, there are known 16 compounds or other compounds. These compounds are 1, 2:
5,6-D-isopropylidene-α-D-glucofuranose 31 dissolved in an appropriate solvent, 1 to 2 equivalents + 1'
0,) 1 to 2 equivalents of alkyl or alkenyl halide in the presence of a strong base such as sodium hydride [) to ε3
It can be easily produced by reacting at -0°C for 5 to 10 hours. As a solvent, benzene, toluene, zooginane, detrahydrofuran, zomethylsulfogide, dimethylformamide, etc. can be used, but sometimes dimethylsulfoxy is preferred. That's awesome.

次に析くして得られfこ本発明化合物のうち、代表的な
ものン第1表に争げ、そのi江楠1乍用及び、淋性嵩性
について試験し1こ+li#液ケ示−[0以ド余白 ill’  Leukemia L −5178Yに対
1−る1冗、ral @作用 111? 4% 5ill l)mとしてLeukem
ia L −5178Y 乞用い机1,9作用ケ調ベム
ニ。10襲の牛胎児血清ゲ含むRPrJI 1640椿
池中にL−5178Y、1胞と1x1υ5 +11!!
1 /lnlとなるようにとり、さらに試料馨l′Jテ
定の、r4度加えたのち、37゛Cで5%炭酸ガスイン
ギュベーター中で48時l1」端書し友。」き猾終了陵
・、・細)赳数馨計故し、対照に対する夷懺弁のポ11
11皿JW頂率r衣め1こ。この値乞%j故確率紙上に
デアロットしこれから■C50ン求め定。この結米ン第
2表に示す。
Next, representative compounds of the present invention obtained by analysis are shown in Table 1, and tested for their phosphorescence and bulkiness. - [0 or more margin ill' Leukemia L 4% 5ill l)m as Leukem
ia L-5178Y Begging desk 1,9 action case style bemuni. RPrJI containing 10 doses of fetal bovine serum 1640 Tsubakiike, L-5178Y, 1 cell and 1x1υ5 +11! !
1/lnl, and after adding 4 degrees of R to the sample, heat it at 37°C in a 5% carbon dioxide incubator for 48 hours. ``The end of the battle... Thin) Kaoru Kaoru made a mistake, and compared to the contrast, Po. 11
11 dishes JW top rate r batter 1 piece. This beggar %j is dealt with on the probability paper, and from this ■C50 is determined. This rice is shown in Table 2.

以下余白 42表 (2L  P 388 (c対する+H(1vi作1−
441イ1°P6四〇)I−3Dド゛1糸−11f、性
マウスについて、このマウスの1j鷺11〆内に1匹7
は1 [J51同のP6ε38.トltl +1lI2
ン序殖し、24時間rをより生・1已1k l!f r
Kにmlミ凋した破侠化合物ケ1F31回6CJn19
/曽づつ5日間連続して11νlI’、E内に投4した
。゛稍4.+11制し凱後の谷マウスα戸土イf日叔よ
りILS (%)ケ求め、その延6δ幼米よりJ丸1+
¥i +舌1〆IE Y *;1mべfこ。この結果を
第6表に示も第3表 (3)1拍、性毒性 本光明抗J+V) >i’lに使用される代茨的化fγ
物ケ生理1走1諸Mfにdj仔ないし愁l蜀し、1イ拝
5匹のJ、Iii eマウスリ屓ガ名内に投与し、7日
1ijl M M r1児祭[また。そのl青果5 [
J Oll1y / tagの投与f辻において何れの
マウスも生(rし、異材はtJりられなかつ1こ。i疋
つぞ第4表に示−in<、イuiれの化合物もLD5o
は5 o−’ir〕llノ/My以上であり、毒t’l
: Iま庫ろ−〔弱い。
The following margins are 42 tables (2L P 388 (c for +H (1vi work 1-
441 I1°P6 40) I-3D Do1 Thread-11f, regarding the sex mice, 1 animal within 1j heron 11〆 of this mouse 7
is 1 [J51 same P6ε38. Toltl +1lI2
In order to incubate and grow for 24 hours, it is possible to produce 1 kl! f r
K has a ml-decreased chivalry compound ke 1F31 times 6CJn19
/Zeng was cast in 11νlI', E for 5 consecutive days. 4. After winning +11, I obtained ILS (%) from α Todo If Nisshu, and J Maru 1+ from the total 6δ young rice.
¥i + tongue 1〆IE Y *;1mbefko. The results are shown in Table 6.
Inject one mouse into one Mf and administer it to five mice per day, and give it to one mouse for 7 days. Part 1 Fruits and vegetables 5 [
None of the mice were born at the same time as the administration of JOll1y/tag.
is more than 5 o-'ir]ll/My, and poison t'l
: Imakoro - [Weak.

弔dイ艶 次に、lt+r < してf4+られゐ本発明の尻t、
s’i削の投与方法及び投り岐ン示す〇 投与方法け1.6.+8剤、カブ士ルj1す、1′Q拉
1′1す、シロツ′7°列斗に、1:る4マ(「1投与
、′y、は注射11すとしてIi下、H4肉内、III
IJ IQ内あるイf:E、 Il+’(’廃肉IX 
4 s −h シ< ハ龜イi等と混合して魚肉と仁く
)か、川【相バクとl卦C非経口投与も町Uヒである。
The end of the present invention, lt + r < then f4 +
1.6. +8 drug, Kabushi Ruj1su, 1'Qla1'1su, Shirotsu'7° column, 1:ru4ma ('1 administration,'y,'y, as injection 11th, Ii lower, H4 intramuscular ,III
If in IJ IQ: E, Il+'('Waste meat IX
4 s - h し < は 龜い i etc. (mixed with fish meat), or 川 [あいばくとl 卦C Parenteral administration is also recommended.

投与Pd°は、投与経吊により異なり、通常、成人。Dosage Pd° varies depending on the route of administration and is usually for adults.

において、経口投与の場合i、o〜20 o〃v/+C
p。
In the case of oral administration, i, o ~ 20 o〃v/+C
p.

非経口投与の場合LJ、5〜1uo+w/にgが適当で
あ句 0 経口用削と−「るには、通常の製浦方法に従って4造し
rする。即ち、デンプン、乳塘、マンニトール勢の1に
4ν(す、カルノ1ぐキシメチルセルロースナトリウム
、ヒげロギシデロビルセルロース等の精a削、IM 晶
(ルロース、カルJ1ぐギシメチルセルロースカルシウ
ム停の崩′壊剤、タルク、ステアリン淑マグネシウム等
の滑沢剤、軽′ぼ燕lkケイr浚浄の?lIe!I:b
畦向ヒ削等?]1凌目:組み合すて処方することにより
、−削、カプセル剤、顆粒剤等f?f製令し得る。
For parenteral administration, LJ, 5 to 1 uo+w/g is suitable. In 1, 4ν (sodium carboxymethylcellulose, refined abrasion of siderobil cellulose, etc.), IM crystal (lulose, disintegrating agent of calcium methylcellulose, talc, magnesium stearin) Lubricants such as, light 'bo yankkei r dredging?lIe!I:b
A ridge cut, etc.? ] 1st plan: By combining and prescribing, -shavings, capsules, granules, etc. f can be ordered.

非経口用剤において、注射剤41の水溶液形態で用いる
場合は、イ【発明化合物、例えば化合物番号6等は水、
生理食塩水等に浴岬するので、常法によY)、注射剤等
を製造し得る。
In parenteral preparations, when using the injection 41 in the form of an aqueous solution, (i) the invention compound, such as compound number 6, is
Since the product is soaked in physiological saline or the like, injections and the like can be manufactured using conventional methods.

坐刹ン映するには、曲常団用される基剤、例えば、カカ
オ脂、合成油脂等に本発明化合:吻馨常法により汁敗′
後同化して映する。
To make a zasha, the compound of the present invention is added to a base commonly used in music, such as cacao butter, synthetic oil, etc., by a conventional method.
Later assimilate and project.

次に参考圀醍び実施1す11馨φげ、更に本ダ^明を・
説明−「る。
Next, we will introduce the reference field practice 1st 11th grade, and then write the main text.
Explanation: “Ru.

参考例1゛ D−グルコース−3−1,1−ラウリルエーテルの合成
: 6−IJ−ラウリル−1,2:5.6−シー+J’−イ
ンプロピリデン−α−D−グルコフラノース2.07 
、</な4 [4,7+lの水に(繰濁し、アンパーラ
イトCG−120(1N+詰りで処理したもの”) 1
.511加え、24時間還流する。放冷慢吸引(J51
1φ水洗する。残ll11γメタノールに清!’部し、
1戸;尚して、1戸c伐ン01縮すると結−晶化する。
Reference Example 1 Synthesis of D-glucose-3-1,1-lauryl ether: 6-IJ-lauryl-1,2:5.6-C+J'-impropylidene-α-D-glucofuranose 2.07
,</na4 [4,7+l of water (suspended, treated with Amperlite CG-120 (1N+clogged)") 1
.. 511 was added and refluxed for 24 hours. Cold lax suction (J51
Wash with 1φ water. Clean the remaining 11γ methanol! 'Part,
1 unit: Furthermore, when 1 unit is reduced, it crystallizes.

イソゾロにルアフレコールより丙、晴晶″[ると)残色
j[状晶1゜03g得られる。(収率61.2慢)1 夷痢1++11 (M削) l〕−グルコース−3−0−オクタ デシルエーテル(化合物番号13)   10(JII
l&D−マンニトール         150#り結
晶セルロース           50)ILyバレ
イショデン1ン         2 Bmyカル+l
? キシメチルセルロースカルシウム タルク                4 rtb;
)ステアリン酸マグネシウム        2 In
9討Ht(             5 5 0 ”
’9よml+i14分馨とり、、・ル′法により、fう
N/’il11昭ケ製する。
1゜03g of crystals with a residual color of 1゜03g are obtained from Rua Flecole to Isozoro.〕-Glucose-3-0- Octadecyl ether (compound number 13) 10 (JII
l&D-mannitol 150# crystalline cellulose 50) ILy potato den 1 2 Bmycal+l
? oxymethylcellulose calcium talc 4 rtb;
) Magnesium stearate 2 In
9th investigation Ht ( 5 5 0 ”
9 mL + 14 minutes, 11 minutes was prepared using the method.

実施例2(カプセル削) 化合!吻許号9の化合′吻        2 5 +
11!,1結晶セルU−ス           i 
7m9串盾 ’if ス1氏 ノk ケ イ 1り  
                         
      7 l,7ステアリンrノマグネシウム 
       11η9全  iオ         
   1801す上記成分ケとり、′ポ法により顆粒7
1回し、6号カッセル111Mに充填する。
Example 2 (capsule cutting) Combination! Compound of proboscis number 9' proboscis 2 5 +
11! , 1 crystal cell U-s i
7m9 skewer shield 'if Su1 Mr. Nok Kay 1ri

7 l,7 stearin magnesium
11η9 all io
1801 Remove the above ingredients and make granules 7 using the 'PO method.
Fill the No. 6 cassel 111M once.

央殉例3(注射剤) D−グルコース−3〜E1−オフナルエーテル(化合物
番号6 ) 5 CJm9ン生L!4! ’IJ 塩/
k テ浴1% L,、辛酸2 m13とする。常法によ
り、メンブランフィルタ−?用いてVtli IA i
’戸I尚しムニ(tl ガラス了ンフ0ルに充填、融閉
し、74:、君国とする。
Central case 3 (injection) D-glucose-3~E1-ofnal ether (compound number 6) 5 CJm9 raw L! 4! 'IJ Salt/
k Te bath 1% L, spicy acid 2 m13. Membrane filter -? Using Vtli IA i
'The door is filled with glass, melted and sealed, and becomes a princely state.

火砲1’/In(頓孜用乳化iす) 梢・伎太ヴ油           I II IJ 
g、IH製卵黄レシチン         12!I住
射用り゛リセリン         25g注射用蒸留
水で全せ       11と1−る本品の千即枚l1
1ii故に討−(°ろ(そ嶺圧比は約1である。
Cannon 1'/In (emulsified isu for Tonkei) Kozue/Kita V oil I II IJ
g, IH egg yolk lecithin 12! I 25g of lycerin for injections, complete with distilled water for injections, 1,000 pieces of this product 11
1ii Therefore, the slope pressure ratio is approximately 1.

実桶例5(坐削) 化合物番号12の化合′吻      5 LI I1
1!ノ上配++15分ケとり、常法により、浴融、1・
−押抜、成ノ19同化し坐削1個χ製する。
Actual case example 5 (sitting) Compound No. 12 compound's proboscis 5 LI I1
1! Remove the upper layer for 15 minutes, melt in the bath by the usual method, and
- Pushing, assimilating Seino 19 and making 1 piece χ.

手続抽圧書(自発〕 昭和57年12月L7日 特許庁12官看 杉 和夫殿 2 発明の名称 抗癌剤 住 所 束憩都中央区日本杭浜町2丁目12査4号名 
称 ニスニス製楽株式会社 代表名泰道直方 6、 抽圧の対象 明細招の「発明の詳細な説明」の欄。
Procedural summary document (spontaneous) December L7, 1980 Patent Office 12th official Kazuo Sugi 2 Name of the invention Anticancer agent Address 4, 2-12, Nihon Kuihama-cho, Chuo-ku, Tsukaikito
Name: Nisnis Seiraku Co., Ltd. Representative Name: Nookata Yasumichi 6, "Detailed Description of the Invention" column of the subject matter of extraction.

7、@止の内在 (1)  明和1畳中、第2頁、最下行r Veahc
haatuan Jとあるを、I Vi+@hchem
tuam Jと削正する。
7, @The immanence of stop (1) Meiwa 1 tatami medium, page 2, bottom row r Veahc
haatuan J and I Vi+@hchem
Revised as tuam J.

(2)1司、 第 3 貞、 第 3行r ussnに
」とあるを、 r USSR,に」と訂正する。
(2) In the 1st Tsukasa, 3rd Sada, 3rd line, ``R ussn'' is corrected to ``R USSR, ni''.

Claims (1)

【特許請求の範囲】 1 次の式flJ H C式’P、Rは炭*数1〜60のアルキルまたはアルケ
ニル基ケ示j) で表わされゐD−グルコース−6−o−アルキル若しく
はアルケニルエーテルヶ有効成分としてよ有fる抗癌剤
[Scope of Claims] 1 D-glucose-6-o-alkyl or alkenyl represented by the following formula flJ H C formula 'P, R are carbon * alkyl or alkenyl group having 1 to 60 j) Ether is a very useful anticancer agent as an active ingredient.
JP57156739A 1982-09-10 1982-09-10 Carcinostatic agent Granted JPS5946222A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57156739A JPS5946222A (en) 1982-09-10 1982-09-10 Carcinostatic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57156739A JPS5946222A (en) 1982-09-10 1982-09-10 Carcinostatic agent

Publications (2)

Publication Number Publication Date
JPS5946222A true JPS5946222A (en) 1984-03-15
JPH0136809B2 JPH0136809B2 (en) 1989-08-02

Family

ID=15634256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57156739A Granted JPS5946222A (en) 1982-09-10 1982-09-10 Carcinostatic agent

Country Status (1)

Country Link
JP (1) JPS5946222A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077963A1 (en) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais Saccharide and itol derivatives having an o-alkyl group or an o-alkyl group and an o-n butanyl group, uses as medicines in tumoral or benign proliferative pathologies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55154991A (en) * 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
JPS5788192A (en) * 1980-11-21 1982-06-01 Hisamitsu Pharmaceut Co Inc Beta-d-mannofuranoside derivative
JPS5788190A (en) * 1980-11-21 1982-06-01 Hisamitsu Pharmaceut Co Inc Beta-d-ribofuranoside derivative
JPS5788191A (en) * 1980-11-21 1982-06-01 Hisamitsu Pharmaceut Co Inc Beta-l-rhamnopyranoside derivative
JPS5788189A (en) * 1980-11-21 1982-06-01 Shoei Eda Beta-l-sorbopyranoside derivative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55154991A (en) * 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
JPS5788192A (en) * 1980-11-21 1982-06-01 Hisamitsu Pharmaceut Co Inc Beta-d-mannofuranoside derivative
JPS5788190A (en) * 1980-11-21 1982-06-01 Hisamitsu Pharmaceut Co Inc Beta-d-ribofuranoside derivative
JPS5788191A (en) * 1980-11-21 1982-06-01 Hisamitsu Pharmaceut Co Inc Beta-l-rhamnopyranoside derivative
JPS5788189A (en) * 1980-11-21 1982-06-01 Shoei Eda Beta-l-sorbopyranoside derivative

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077963A1 (en) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais Saccharide and itol derivatives having an o-alkyl group or an o-alkyl group and an o-n butanyl group, uses as medicines in tumoral or benign proliferative pathologies

Also Published As

Publication number Publication date
JPH0136809B2 (en) 1989-08-02

Similar Documents

Publication Publication Date Title
CN109111501A (en) The indoles alcohol derivative of fatty acid/amino acid modification, synthesis, activity and application
JP6851652B2 (en) Application of IDHP in the preparation of drugs or dietary supplements for the prevention and treatment of coronary atherosclerosis
Kendall A chemical and physiological investigation of the suprarenal cortex
Hevesy et al. The origin of the phosphorus compounds in the embryo of the chicken
Andervont et al. Dibenzanthracene Tumors in Mice: The Production of Subcutaneous, Pulmonary, and Liver Tumors by Serum Dispersions and Lard Solutions
Hill et al. Fatal DDT poisoning
Bodman et al. The α-glyceryl ethers
JPS6112622A (en) Agent for promoting differentiation and proliferation of hemopoietic stem cell
Landauer Complex formation and chemical specificity of boric acid in production of chicken embryo malformations.
Dam The formation of coprosterol in the intestine: Possible role of dihydrocholesterol, and a method of determining dihydrocholesterol in presence of cholesterol
JPS5946222A (en) Carcinostatic agent
Carroll Isolation of an anti-thyroid compound from rape seed (Brassica napus)
CN105193795A (en) Application of two halogen-phenol compounds to effect of promoting angiogenesis
Anderson et al. Toxicological studies on synthetic glycerin
Aylward et al. The liver and fat metabolism
Robinson et al. Clinical and pathological details of two cases of phaeochromocytoma in childhood
D'Silva Action of adrenaline-like substances on the serum potassium
Hueper Experimental Studies in Cardiovascular Pathology: XI. Thesaurosis and Atheromatosis Produced in Dogs by the Repeated Intravenous Injection of Solutions of Sodium Cellulose Glycollate
Peck Attempts at treatment of hemorrhagic diathesis by injections of snake venom
Hughes et al. Influence of ultra-violet light on young laying hens
Magee et al. Studies on the movements of the alimentary canal: I. The effects of electrolytes on the rhythmical contractions of the isolated mammalian intestine
Baldwin et al. Interaction of heat and X-rays in killing a chalcid
Taylor et al. The Mobilization and Excretion of Calcium Following Overdosage with Irradiated Ergosterol
Zamecnik et al. Protection of Animals Against CI. welchii (Type A) Toxin by Injection of Certain Purified Lipids.
Monroe et al. Thyroid secretion rate of albino rats during growth, pregnancy and lactation